Evidence map›Paper›PMID 22673616›Full record

ArticleAmerican journal of physiology. Cell physiology2012

Regulation of the human Na+-dependent glucose cotransporter hSGLT2.

Chiara Ghezzi, Ernest M Wright

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. A lipid atlas of the human kidney.Science advances · 2025
    Article
  8. Article
  9. SGLT2 Inhibitors and Uric Acid Homeostasis.Gout, urate, and crystal deposition disease · 2024
    Article
  10. Review
  11. Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects.The Journal of clinical endocrinology and metabolism · 2023
    Article
  12. Article
  13. Review
  14. Renoprotective Effects of SGLT2 Inhibitors.Heart failure clinics · 2022
    Review
  15. Review
  16. The sugar daddy: the role of the renal proximal tubule in glucose homeostasis.American journal of physiology. Cell physiology · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Human Glucose Transporters in Renal Glucose Homeostasis.International journal of molecular sciences · 2021
    Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chiara GhezziDepartment of Physiology, David Geffen School of Medicine, Univeristy of California at Los Angeles, Los Angeles, California 90095-1751, USA. cghezzi@mednet.ucla.edu
Ernest M Wright
University of California, Los Angeles · US

Funding

MOLECULAR MECHANISMS OF INTESTINAL TRANSPORTR01DK019567 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WRIGHT, ERNEST M · 1986 to 2013
$4.3M
Role of SGLTs in Glucose Homeostasis and Tissue MetabolismR01DK077133 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WRIGHT, ERNEST M · 2008 to 2011
$1.3M
NIDDK NIH HHS DK-19567NIDDK NIH HHS DK-77133
6 · The paper itself

Abstract

The human Na(+)-glucose cotransporter SGLT2 is expressed mainly in the kidney proximal convoluted tubule where it is considered to be responsible for the bulk of glucose reabsorption. Phosphorylation profiling has revealed that SGLT2 exists in a phosphorylated state in the rat renal proximal tubule cortex, so we decided to investigate the regulation of human SGLT2 (hSGLT2) by protein kinases. hSGLT2 was expressed in human embryonic kidney (HEK) 293T cells, and the activity of the protein was measured using radiotracer and whole cell patch-clamp electrophysiology assays before and after activation of protein kinases. 8-Bromo-adenosine cAMP (8-Br-cAMP) was used to activate protein kinase A, and sn-1,2-dioctanoylglycerol (DOG) was used to activate protein kinase C (PKC). 8-Br-cAMP stimulated D-[α-methyl-(14)C]glucopyranoside ([(14)C]α-MDG) uptake and Na(+)-glucose currents by 200% and DOG increased [(14)C]α-MDG uptake and Na(+)-glucose currents by 50%. In both cases the increase in SGLT2 activity was marked by an increase in the maximum rate of transport with no change in glucose affinity. These effects were completely negated by mutation of serine 624 to alanine. Insulin induced a 250% increase in Na(+)-glucose transport by wild-type but not S624A SGLT2. Parallel studies confirmed that the activity of hSGLT1 was regulated by PKA and PKC due to changes in the number of transporters in the cell membrane. hSGLT1 was relatively insensitive to insulin. We conclude that hSGLT1 and hSGLT2 are regulated by different mechanisms and suggest that insulin is an SGLT2 agonist in vivo.

Indexed as

8-Bromo Cyclic Adenosine MonophosphateCyclic AMP-Dependent Protein KinasesDiglyceridesElectrophysiological PhenomenaGlucoseHEK293 CellsHumansInsulinKidneyMutationProtein Kinase CProtein Kinase InhibitorsSodium-Glucose Transporter 21,2-dioctanoylglycerol8-Bromo Cyclic Adenosine MonophosphateCyclic AMP-Dependent Protein KinasesDiglyceridesGlucoseInsulinProtein Kinase CProtein Kinase InhibitorsSLC5A2 protein, humanSodium-Glucose Transporter 2

Identifiers

PMID22673616
PMCPMC3423026
OpenAlexW2099111050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.